Advisor Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $12.7M | Buy |
241,875
+20,282
| +9% | +$1.03M | 0.89% | 15 |
|
|
2022
Q1 | $11.5M | Sell |
221,593
-2,242
| -1% | -$116K | 0.72% | 19 |
|
|
2021
Q4 | $13.2M | Sell |
223,835
-1,054
| -0.5% | -$52.2K | 0.8% | 17 |
|
|
2021
Q3 | $9.67M | Sell |
224,889
-6,168
| -3% | -$273K | 0.65% | 27 |
|
|
2021
Q2 | $9.05M | Buy |
231,057
+206
| +0.1% | +$8.01K | 0.59% | 27 |
|
|
2021
Q1 | $8.36M | Sell |
230,851
-18,529
| -7% | -$658K | 0.6% | 31 |
|
|
2020
Q4 | $9.18M | Buy |
249,380
+13,356
| +6% | +$490K | 0.69% | 28 |
|
|
2020
Q3 | $8.22M | Buy |
236,024
+29,995
| +15% | +$1.05M | 0.71% | 29 |
|
|
2020
Q2 | $6.39M | Sell |
206,029
-1,595
| -0.8% | -$54.2K | 0.6% | 36 |
|
|
2020
Q1 | $6.43M | Sell |
207,624
-769
| -0.4% | -$26.2K | 0.78% | 28 |
|
|
2019
Q4 | $8.04M | Buy |
208,393
+33,395
| +19% | +$1.19M | 0.83% | 22 |
|
|
2019
Q3 | $5.97M | Sell |
174,998
-5,502
| -3% | -$200K | 0.72% | 29 |
|
|
2019
Q2 | $7.42M | Sell |
180,500
-4,081
| -2% | -$162K | 0.9% | 18 |
|
|
2019
Q1 | $7.44M | Sell |
184,581
-3,292
| -2% | -$132K | 0.95% | 16 |
|
|
2018
Q4 | $7.78M | Buy |
187,873
+20,387
| +12% | +$846K | 1.24% | 8 |
|
|
2018
Q3 | $7M | Buy |
167,486
+9,092
| +6% | +$350K | 0.94% | 16 |
|
|
2018
Q2 | $5.45M | Buy |
158,394
+10,002
| +7% | +$342K | 0.92% | 19 |
|
|
2018
Q1 | $5M | Buy |
148,392
+6,537
| +5% | +$225K | 0.92% | 16 |
|
|
2017
Q4 | $4.97M | Buy |
141,855
+14,735
| +12% | +$502K | 0.89% | 16 |
|
|
2017
Q3 | $4.31M | Buy |
127,120
+6,420
| +5% | +$206K | 0.85% | 18 |
|
|
2017
Q2 | $3.85M | Buy |
120,700
+1,142
| +1% | +$36K | 0.9% | 23 |
|
|
2017
Q1 | $3.88M | Buy |
119,558
+18,491
| +18% | +$583K | 1.03% | 17 |
|
|
2016
Q4 | $3.11M | Buy |
101,067
+1,518
| +2% | +$46.3K | 0.94% | 22 |
|
|
2016
Q3 | $3.2M | Sell |
99,549
-963
| -1% | -$32.2K | 1.07% | 17 |
|
|
2016
Q2 | $3.36M | Buy |
100,512
+7,735
| +8% | +$247K | 1.18% | 12 |
|
|
2016
Q1 | $2.61M | Sell |
92,777
-15,539
| -14% | -$444K | 0.97% | 22 |
|
|
2015
Q4 | $3.32M | Sell |
108,316
-770
| -0.7% | -$24.2K | 1.13% | 13 |
|
|
2015
Q3 | $3.27M | Buy |
109,086
+8,846
| +9% | +$284K | 1.37% | 9 |
|
|
2015
Q2 | $3.29M | Buy |
100,240
+16,231
| +19% | +$529K | 1.26% | 8 |
|
|
2015
Q1 | $2.77M | Buy |
84,009
+5,953
| +8% | +$189K | 1.18% | 8 |
|
|
2014
Q4 | $2.3M | Sell |
78,056
-2,680
| -3% | -$76.8K | 1.02% | 17 |
|
|
2014
Q3 | $2.27M | Sell |
80,736
-7,931
| -9% | -$223K | 1.3% | 14 |
|
|
2014
Q2 | $2.5M | Sell |
88,667
-1,915
| -2% | -$54.6K | 1.23% | 10 |
|
|
2014
Q1 | $2.76M | Buy |
90,582
+3,519
| +4% | +$105K | 1.52% | 7 |
|
|
2013
Q4 | $2.53M | Buy |
87,063
+7,276
| +9% | +$212K | 1.46% | 8 |
|
|
2013
Q3 | $2.17M | Buy |
79,787
+2,793
| +4% | +$76K | 1.55% | 7 |
|
|
2013
Q2 | $2.05M | Buy |
+76,994
| New | +$2.13M | 1.68% | 7 |
|
Other funds holding PFE
Advisor Partners's PFE Position: Q2 2022 in Review
Advisor Partners increased its Pfizer (PFE) stake by 9.2% in Q2 2022, buying an estimated $1.03M and bringing the position to 241,875 shares worth $12.7M. The position accounts for 0.89% of the portfolio, ranked #15.
Advisor Partners first reported a position in PFE in Q2 2013 and has held it in 37 quarters since. The position peaked at $13.2M in Q4 2021. 3,158 funds tracked by Wall St. Rank hold PFE as of Q2 2022.
- Advisor Partners held 241,875 shares of Pfizer worth $12.7M as of Q2 2022.
- Advisor Partners bought 20,282 Pfizer shares in Q2 2022, an estimated $1.03M.
- Pfizer made up 0.89% of Advisor Partners's portfolio in Q2 2022, its #15 holding.
- Advisor Partners first reported a position in Pfizer in Q2 2013 and has held it in 37 quarters since.
- Advisor Partners's Pfizer position peaked at $13.2M in Q4 2021.
- 3,158 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.
Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.